Loading
Everything OnCo dates to 1993: 43 entries, 21 landmarks, 6 companies founded, 5 papers and 5 papers listed on people's pages. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
43 dated entries in OnCo fall in 1993: 21 landmarks, 6 companies founded, 5 papers, 5 papers listed on people's pages, 4 approvals, 1 journal founded and 1 trial reported.
Of those, 43 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Active hairy cell leukaemia
Anaemia due to concomitant myelosuppressive chemotherapy in non-myeloid malignancies
Prevention of nausea and vomiting from emetogenic chemotherapy (Kytril; radiotherapy later)
Anorexia, cachexia or unexplained weight loss in AIDS (oral suspension)
The year reported on trial records, with the headline result the record gives.
Thirteen-year colorectal cancer mortality 5.88 per 1,000 with annual screening against 8.83 in controls, a 33 percent reduction.
The publication year on key paper records.
Aaronson NK, Ahmedzai S, Bergman B, et al. JNCI: Journal of the National Cancer Institute.
Cella DF, Tulsky DS, Gray G, et al. Journal of Clinical Oncology.
El-Deiry WS, Tokino T, Velculescu VE, et al. Cell.
Mandel JS, Bond JH, Church TR, et al. New England Journal of Medicine.
Wotherspoon AC, Doglioni C, Diss TC, et al. The Lancet.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Paediatric low-grade glioma. Packer and colleagues show chemotherapy can defer radiotherapy in young children.
Diffuse large B-cell lymphoma
Marginal zone lymphoma
Systemic mastocytosis. Nagata and colleagues (1995) confirm the activating mutation in most patients.
Biliary tract cancer (cholangiocarcinoma)
Liposarcoma
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Mismatch-repair deficient (MSI-high) colorectal cancer
Vestibular schwannoma (acoustic neuroma). Trofatter and Rouleau identify the merlin tumour suppressor on chromosome 22.
Meningioma. Trofatter and Rouleau clone the gene whose loss drives most meningiomas and schwannomas.
Ductal carcinoma in situ (DCIS). Halves local recurrence; no survival difference.
Rhabdomyosarcoma
Colorectal cancer. The National Polyp Study found 76 to 90 percent fewer cancers than expected in 1,418 patients whose adenomas were removed; in the same year the Minnesota trial s...
Relapsed and refractory classical Hodgkin lymphoma
Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4). Mulligan and colleagues, Nature; Donis-Keller and colleagues.
Medullary thyroid cancer
Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)
Colorectal cancer. Nottingham (1996, 152,850 people, 15 percent reduction) and Funen (1996, 18 percent) follow the Minnesota result and build the case for national programmes.
Clear cell renal cell carcinoma
Spinal cord tumours (intramedullary and intradural). Haemangioblastoma of the cord and cerebellum recognised as a hallmark of the syndrome.
Renal cell carcinoma
The founded year on company records.
Princeton, NJ
Wiesbaden
Paris
San Francisco, California, United States
Hyderabad
Bengaluru
The founded year on journal records.
Springer Nature
The selected publications each biography lists, which is a reading of that person rather than a reading of the year.
The Lancet
New England Journal of Medicine
Proceedings of the National Academy of Sciences
Journal of the American Statistical Association
New England Journal of Medicine